S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
NASDAQ:RCM

R1 RCM - RCM Stock Forecast, Price & News

$14.56
+0.26 (+1.82%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$14.23
$14.65
50-Day Range
$12.42
$14.89
52-Week Range
$6.71
$27.86
Volume
2.11 million shs
Average Volume
2.69 million shs
Market Capitalization
$6.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.85

R1 RCM MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
15.7% Upside
$16.85 Price Target
Short Interest
Bearish
9.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.79mentions of R1 RCM in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$999,714 Bought Last Quarter
Proj. Earnings Growth
138.89%
From $0.18 to $0.43 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Business Services Sector

70th out of 328 stocks

Management Services Industry

1st out of 7 stocks


RCM stock logo

About R1 RCM (NASDAQ:RCM) Stock

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.

Receive RCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

RCM Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Revenue Cycle Management (RCM) Global Market Report 2023
Q4 2022 Cymabay Therapeutics Inc Earnings Call
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
R1 RCM (RCM) Faced Multiple Challenges in Q4
R1 RCM, Inc. (RCM) Q4 2022 Earnings Call Transcript
R1 RCM Full Year 2022 Earnings: EPS Misses Expectations
Why R1 RCM Stock Is Surging Today
R1 RCM Reports Fourth Quarter and Full Year 2022 Results
R1 RCM Inc. (RCM) Reports Q4 Loss, Tops Revenue Estimates
R1 RCM Earnings Preview
See More Headlines
Receive RCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

RCM Company Calendar

Last Earnings
2/16/2023
Today
3/27/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Management services
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:RCM
CUSIP
00438V10
Employees
22,000
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$16.85
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+16.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-57,600,000.00
Pretax Margin
-3.38%

Debt

Sales & Book Value

Annual Sales
$1.81 billion
Cash Flow
$0.29 per share
Book Value
$6.53 per share

Miscellaneous

Free Float
169,165,000
Market Cap
$6.01 billion
Optionable
Not Optionable
Beta
0.82

Social Links


Key Executives

  • Lee Rivas
    Chief Executive Officer & Director
  • John SparbyJohn Sparby
    President
  • Kristina Bourke
    Executive Vice President-Operations
  • Jennifer Williams
    Chief Financial Officer & EVP
  • Harvey Ewing
    Chief Information Officer & Executive VP













RCM Stock - Frequently Asked Questions

Should I buy or sell R1 RCM stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCM shares.
View RCM analyst ratings
or view top-rated stocks.

What is R1 RCM's stock price forecast for 2023?

12 brokerages have issued 12-month price objectives for R1 RCM's shares. Their RCM share price forecasts range from $10.00 to $25.00. On average, they expect the company's stock price to reach $16.85 in the next twelve months. This suggests a possible upside of 16.3% from the stock's current price.
View analysts price targets for RCM
or view top-rated stocks among Wall Street analysts.

How have RCM shares performed in 2023?

R1 RCM's stock was trading at $10.95 at the beginning of 2023. Since then, RCM shares have increased by 32.2% and is now trading at $14.48.
View the best growth stocks for 2023 here
.

When is R1 RCM's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our RCM earnings forecast
.

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) issued its quarterly earnings data on Thursday, February, 16th. The healthcare provider reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.06. The healthcare provider earned $532.80 million during the quarter, compared to the consensus estimate of $519.28 million. R1 RCM had a positive trailing twelve-month return on equity of 0.05% and a negative net margin of 3.19%. The business's revenue for the quarter was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.11 earnings per share.

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM issued an update on its FY 2023 earnings guidance on Friday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.28 billion-$2.33 billion, compared to the consensus revenue estimate of $2.30 billion.

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM Chief Executive Officer Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among the company's employees.

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by a number of institutional and retail investors. Top institutional investors include New Mountain Capital L.L.C. (22.67%), Point72 Asset Management L.P. (2.60%), Sachem Head Capital Management LP (1.63%), American Century Companies Inc. (1.25%), Sunriver Management LLC (1.11%) and Morgan Stanley (1.06%). Insiders that own company stock include Achi Series Lllp Tcp-Asc, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, Lee Rivas, Michael C Feiner and Richard B Jr Evans.
View institutional ownership trends
.

How do I buy shares of R1 RCM?

Shares of RCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $14.48.

How much money does R1 RCM make?

R1 RCM (NASDAQ:RCM) has a market capitalization of $6.03 billion and generates $1.81 billion in revenue each year. The healthcare provider earns $-57,600,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does R1 RCM have?

The company employs 22,000 workers across the globe.

Does R1 RCM have any subsidiaries?
The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Cerner RevWorks, Clearsight Intermediate Holdings Inc., Cloudmed, Flare Capital Partners Investment Company, Intermedix, Intermedix ARM LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Staffing Inc., Medical Consultants Inc., Practice Support Resources LLC, Project Links Parent Inc., Project Roadrunner Merger Sub Inc., Project Roadrunner Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCHEDULING.COM INC., SCI Solutions, Tonic Health LLC, VisitPay, cGate Health Inc., and iVinci Partners LLC.
Read More
How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The official website for the company is www.r1rcm.com. The healthcare provider can be reached via phone at (312) 324-7820, via email at arahim@r1rcm.com, or via fax at 302-655-5049.

This page (NASDAQ:RCM) was last updated on 3/27/2023 by MarketBeat.com Staff